Skip to content

Impact of Artificial Intelligence (AI) on Adenoma Detection During Colonoscopy in FIT+ Patients.

Impact of AI (Artificial Intelligence) on Adenoma Detection During Colonoscopy in FIT+ Patients: a Prospective Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04691401
Acronym
AIFIT
Enrollment
750
Registered
2020-12-31
Start date
2020-12-20
Completion date
2021-12-31
Last updated
2024-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polyp of Colon

Keywords

adenoma detection

Brief summary

The Italian screening program invites the resident population aged 50-74 for Fecal Immunochemical Test (FIT) every 2 years. Subjects who test positive are referred for colonoscopy. Maximizing adenoma detection during colonoscopy is of paramount importance in the framework of an organized screening program, in which colonoscopy represent the key examination. Initial studies consistently show that Artificial iIntelligence-based systems support the endoscopist in evaluating colonoscopy images potentially increasing the identification of colonic polyps. However, the studies on AI and polyp detection performed so far are mostly focused on technical issues, are based on still images analysis or recorded video segments and includes patients with different indications for colonoscopy. At the best of our knowledge, data on the impact on AI system in adenoma detection in a FIT-based screening program are lacking. The present prospective randomized controlled trial is aimed at evaluating whether the use of an AI system increases the ADR (per patient analysis) and/or the mean number of adenomas per colonoscopy in FIT-positive subjects undergoing screening colonoscopy. Therefore Patients fulfilling the inclusion criteria are randomized (1:1) in two arms: A) patients receive standard colonoscopy (with high definition-HD endoscopes) with white light (WL) in both insertion and withdrawal phase; all polyps identified are removed and sent for histopathology examination; B) patients receive colonoscopy examinations (with HD endoscopes) equipped with an AI system (in both insertion and withdrawal phase); all polyps identified are removed and sent for histopathology examination. In the present study histopathology represents the reference standard.

Interventions

DEVICEArtificial Intelligence System (CAD EYE, Fujifilm Co.)

A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.

Sponsors

Valduce Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 74 Years
Healthy volunteers
No

Inclusion criteria

* Consecutive adult (50-74 yrs.) outpatients undergoing colonoscopy in the frame of the FIT-based screening program.

Exclusion criteria

* patients with CRC history or hereditary polyposis syndromes or hereditary non-polyposis colorectal cancer * patients with inadequate bowel preparation * patients in which cecal intubation was not achieved or scheduled for partial examinations * patients with gastrointestinal symptoms * polyps could not be resected due to ongoing anticoagulation preventing resection and pathological assessment

Design outcomes

Primary

MeasureTime frameDescription
ADR10 monthsAdenoma Detection Rate: rate of participants with at least on adenoma detected during colonoscopy
APC10 monthsAdenoma per Colonoscopy: it is determined by dividing the total number of adenomas removed by the total number of colonoscopies performed

Secondary

MeasureTime frameDescription
Adv-ADR10 monthsAdv-ADR: rate of participants with at least on advanced adenoma detected during colonoscopy
SSL-DR:10 monthsSSL-ADR: the serrated lesions with neoplastic potential (sessile serrated lesions-SSA; traditional serrated adenomas - TSA) detection rate.

Other

MeasureTime frameDescription
Impact of Ai on endoscopist with different ADR10 monthsThe variation in ADR will be stratified according the initial ADR of endoscopists participating in the present study

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026